OVERVIEW
[italic]Clostridioides difficile [/italic]can cause a serious infection of the lower intestine, resulting in significant morbidity and sometimes death. The primary risk factor for [italic]C difficile[/italic] infection (CDI) is exposure to broad-spectrum antibiotics, which disrupt the normal composition and function of the gut microbiome. Antibiotics for CDI treatment do not kill bacterial spores, and recurrence is common. Restoring a healthy gut microbiome is therefore often critical for achieving a durable clinical response. In this live CME event, 3 clinician experts will review treatments for recurrent CDI that target the gut microbiome, including fecal microbiota transplantation and emerging live biopharmaceutical products. Faculty will discuss these therapies in the context of interactive patient cases; audience participation will be encouraged through a live Q&A.
Enhance Your Virtual Experience With Backstage Pass!
Join our 15-minute post-symposium conversation connecting the program speakers and audience in an intimate interactive session where you can address case-based questions, gain valuable insights, and facilitate relationship building. Participation with video encouraged.
GOAL STATEMENT
The goal of this activity is to provide live education on the latest data and recommendations for microbiome therapeutics and where they fit into the treatment of recurrent [italic]C difficile[/italic].
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have increased knowledge regarding the [LIST] [ITEM]Key data for microbiome-directed treatments for recurrent CDI [ITEM]The role of the gut microbiome in recurrent CDI [/LIST] Have greater competence related to [LIST] [ITEM]Management of patients with recurrent CDI [/LIST]
ACCREDITATION STATEMENT
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. [JALOGO] [MEDSCAPE]
[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 1.5 [italic][bold]AMA PRA Category 1 Credit(s)™[/bold][/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity. [bold]For Pharmacists[/bold] Medscape designates this continuing education activity for 1.50 contact hour(s) (0.150 CEUs) (Universal Activity Number: JA0007105-0000-22-284-L01-P).
Marriott Marquis Washington, DC
Room: Liberty Salon I+J+K+L
901 Massachusetts Ave NW
Washington, DC, 20001
United States
Supported by an independent educational grant from [bold]Seres Therapeutics, Inc.[/bold] & [bold]Aimmune Therapeutics[/bold]